Veterinary Record 170:207 doi:10.1136/vr.100306
  • Research
  • Short Communication

Preferential accumulation of meloxicam in inflamed synovial joints of dogs

Open Access
  1. R. Narbe, MSc, DVM, PhD2
  1. IPL, Boehringer Ingelheim, Ingelheim, Germany
  2. Vetmedica, Boehringer Ingelheim, Ingelheim, Germany
  1. E-mail for correspondence laura.johnston{at}

MELOXICAM is a NSAID classified as a derivative of enolic acid, licensed to treat acute and chronic musculoskeletal disorders in the dog. Meloxicam achieves maximal plasma concentration 4.5 hours after oral administration, has a low volume of distribution (0.3 l/kg), is highly plasma protein bound (97 per cent) and has an elimination half-life of 24 hours in dogs (EMA 2011). Steady state pharmacokinetics are achieved within one day using the licensed dose rate in the dog (EMA 2011).

Preferential accumulation and persistence of meloxicam in inflamed joints of both the rat and the human being have previously been documented (Busch and Engelhardt 1990, Lapicque and others 2000).

The objective of this study was to investigate the concentration of meloxicam in the synovial fluid of inflamed joints versus non-inflamed joints in dogs at the lowest plasma concentration (ie, trough level), 24 hours postdosing.

Materials and methods

Eight healthy male dogs (mean age 17.8±3.5-months-old, mean bodyweight 12.59±0.83 kg) were treated with 0.2 mg/kg of meloxicam (Metacam oral suspension) on Day 1 and 0.1 mg/kg of meloxicam on Day 2. All treatments were administered orally. On Day 3, inflammation was …

Open Access

Sign up for job alerts

Vet Record Careers features a comprehensive database of vet jobs.
Browse for your next job, or set personalised job alerts so you hear about vacancies as soon as they go online.
Find out more at Vet Record Careers

Free Sample Issue

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of the Veterinary Record.
View free sample issue >>

Navigate This Article